German Center for Diabetes Research Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2015
NCT02547519
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

German Center for Diabetes Research

Active Ingredients

Drugs in Phase 4 Trials (2)

empagliflozin (jardiance) (1 trial)

semaglutide (Ozempic) (1 trial)

Drugs in Phase 2 Trials (1)

insulin human (humulin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Fatty Liver (Phase 4)

Liver Diseases (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3